Hyperuricemia - Pipeline Insight, 2026

DelveInsight's, "Hyperuricemia - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hyperuricemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Hyperuricemia: Understanding

Hyperuricemia: Overview

Hyperuricemia is defined as an elevated serum uric acid level, usually greater than 6 mg/dL in women and 7 mg/dL in men. Hyperuricemia causes uric acid to clump together in sharp crystals. These crystals can settle in your joints and cause gout, a painful form of arthritis. They can also build up in your kidneys and form kidney stones. Hyperuricemia results from increased uric acid production, decreased excretion, or a combination of both processes.

Hyperuricemia, or high uric acid, often causes no symptoms until it leads to complications like gout or kidney stones. When symptoms do occur, they include intense, sudden joint pain (usually in the big toe), swelling, redness, joint stiffness, and kidney-related issues like flank pain, nausea, or discolored/cloudy urine.

Uric acid is the result of purine breakdown. At the normal physiological pH of 7.4, uric acid circulates in the ionized form of urate. Purine metabolism mainly occurs in the liver but can also happen in any tissue containing xanthine oxidase, such as cardiac or pulmonary tissue. About two-thirds of the body's total production of uric acid is excreted in the kidneys, and a third is passed into the intestine. Urate is filtered and secreted in the kidneys, then 90% is reabsorbed in the proximal tubule. Other mammals have much lower uric acid levels due to the activity of uricase, which converts urate to the more water-soluble allantoin. However, in humans and higher primates, this enzyme is nonfunctional. Purine-rich diets, endogenous purine production, and high cell breakdown accelerate uric acid production.

The etiology of Hyperuricemia involves a combination of increased uric acid production and decreased renal excretion. Overproduction may result from a purine-rich diet (including red meats, organ meats, seafood, and alcohol especially beer) as well as high fructose intake, which enhances uric acid generation through hepatic metabolism. Genetic and metabolic abnormalities, such as hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency and increased phosphoribosylpyrophosphate (PRPP) synthetase activity, also contribute. Additionally, conditions with high cell turnover such as Polycythemia Vera, lymphoproliferative and myeloproliferative disorders, psoriasis, tumor lysis, hemolysis, and rhabdomyolysis can elevate uric acid levels. Decreased excretion is commonly associated with renal impairment, acid-base disturbances (e.g., lactic acidosis, ketoacidosis), and hypovolemia. Various medications and toxins, including diuretics, niacin, pyrazinamide, cyclosporine, lead, and alcohol, further impair uric acid clearance.

The diagnosis of Hyperuricemia is primarily based on laboratory findings, with serum uric acid levels >=8 mg/dL being diagnostic (normal <6.8 mg/dL). Additional tests include 24-hour urinary uric acid measurement (>800 mg/day suggests hyperuricosuria), along with urinalysis showing uric acid crystals, low pH, or hematuria in cases of nephrolithiasis. Blood investigations such as CBC, metabolic panel, and lipid profile help identify underlying conditions, while imaging (renal ultrasound or CT) may detect uric acid stones. Joint aspiration demonstrating needle-shaped, negatively birefringent crystals supports associated gout. Most asymptomatic patients do not require treatment; management is indicated in symptomatic cases or those with complications such as recurrent gout, tophi, or nephrolithiasis. First-line therapy includes xanthine oxidase inhibitors like Allopurinol, with Febuxostat as an alternative. Uricosuric agents (e.g., Probenecid) increase renal excretion of uric acid, while recombinant uricases such as Pegloticase are reserved for refractory cases. Colchicine is commonly used for acute gout and prophylaxis during therapy initiation.

"Hyperuricemia - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperuricemia pipeline landscape is provided which includes the disease overview and Hyperuricemia treatment guidelines. The assessment part of the report embraces, in depth Hyperuricemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperuricemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Hyperuricemia R&D. The therapies under development are focused on novel approaches to treat/improve Hyperuricemia.

Hyperuricemia Emerging Drugs Chapters

This segment of the Hyperuricemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperuricemia Emerging Drugs

• AR882: Sobi

AR882 is a potent and selective inhibitor of uric acid transporter 1 (URAT1), which is responsible for a majority of reabsorption of filtered uric acid from the renal tubular lumen. By inhibiting URAT1, AR882 increases uric acid urinary excretion and thereby lowers serum uric acid (sUA). Preclinically, AR882 has demonstrated inhibitory effect on uric acid uptake and good tolerability in pharmacology, pharmacokinetic and toxicology studies. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Hyperuricemia.

• D-0120: InventisBio Co., Ltd

D-0120 is a novel oral selective uric acid transporter (URAT1) inhibitor being developed for the treatment of hyperuricemia and gout by blocking the reabsorption of uric acid (UA) within the renal proximal tubule, thereby reducing serum uric acid concentrations. As a novel URAT1 inhibitor, D-0120 is anticipated to have more potent serum UA reducing effect than the approved URAT1 inhibitor lesinurad, but with less toxicity and wider therapeutic window. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Hyperuricemia.

• PRX-115: Protalix Biotherapeutics

PRX-115 a recombinant PEGylated uricase enzyme, chemically modified enzyme in development for the potential treatment of uncontrolled gout. PRX-115 is under development for the potential treatment of patients with uncontrolled gout. The uricase enzyme that does not exist naturally in humans converts uric acid to allantoin, which is easily eliminated through urine. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Hyperuricemia.

Hyperuricemia: Therapeutic Assessment

This segment of the report provides insights about the different Hyperuricemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hyperuricemia
• There are approx. 15+ key companies which are developing the therapies for Hyperuricemia. The companies which have their Hyperuricemia drug candidates in the most advanced stage, i.e. phase III include, Sobi.
• Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperuricemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperuricemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperuricemia drugs.

Hyperuricemia Report Insights

• Hyperuricemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hyperuricemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperuricemia drugs?
• How many Hyperuricemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperuricemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hyperuricemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperuricemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sobi
• InventisBio Co., Ltd
• Protalix Biotherapeutics
• Jiangsu HengRui Medicine Co., Ltd.
• Intelligem Therapeutics Australia Pty Ltd.
• Atom Therapeutics
• Shanton Pharma Holdings Limited
• Novo Nordisk A/S
• BioRay Pharmaceutical Co., Ltd.
• 3SBio Inc.

Key Products

• AR882
• D-0120
• PRX-115
• HR091506
• IG3018
• ABP-671
• SAP-001
• NNC4004-0002
• BR2251
• SSS11